, Volume: 12( 1)
The Differential Urinary Metabolite Profiling of Intellectual Disability Disorders Using Untargeted Metabolomics Approach
- Suvidya Ranade , Department of Chemistry, Biochemistry Division, Savitribai Phule Pune University, Pune, Maharashtra, India, Tel: 020-25691728; E-mail: [email protected]
Received: January 01, 2018; Accepted: January 23, 2018; Published: January 29, 2018
Citation: Nikam V, Ranade S. The Differential Urinary Metabolite Profiling of Intellectual Disability Disorders Using Untargeted Metabolomics Approach. Biochem Ind J. 2018;12(1):124
Intellectual disability (ID) is a disorder characterized by cognitive delays. Inborn errors of metabolism constitute an important subgroup of ID for which a number of treatments have become available. We aimed to identify potential urine biomarkers of inherited metabolic disorders from the children with intellectual disability using an untargeted Ultra Performance Liquid Chromatography coupled to Mass Spectroscopy (UPLC-MS) based metabolomics approach. All of the patients were having ID, with IQ less than 70 and no recognizable symptoms for the condition. Eleven compounds have been identified that are up regulated in the ID cohort, three of which are previously reported namely Dopamine, Glutarylglycine and Suberic acid. The physiological significance of these markers is discussed. In conclusion, the results of the study indicate that urinary metabolite analysis of ID using sophisticated analytical high throughput techniques may be an important tool to achieve an early diagnosis and therapy of several metabolic defects, and reflect the underlying biology of ID.
Mass Spectroscopy; Metabolic diseases; Metabolomics; Urinalysis
Metabolomics is a powerful technique used for the comprehensive assessment of global low molecular weight metabolites from a biological sample. It has shown a great potential to facilitate biomarker discovery to differentiate between diseased and non-diseased patients. Metabolite profiling of body fluids has been used for improving the diagnosis, prognosis and therapy of diseases . Metabolites being the end product of cellular processes are the direct outcome of protein and enzymatic activity. Hence, their proximity is more towards phenotype or disease than genetic or proteomic information. It can be referred as a complete catalogue of the human metabolome .
ID refers to a group of developmental conditions characterized by significant impairment of cognitive functions, which are associated with limitations of learning, adaptive behaviour and skills . It affects 1 to 3 percent of general population . It is a complex, variable and heterogeneous disorder. The aetiology is multiple and diagnosis poses a formidable challenge worldwide. Metabolic conditions comprise an important subgroup of ID . Inborn errors of metabolism appear to be a rare cause of developmental delay or intellectual disability. The percentage of patients with identifiable metabolic disorders as cause of the ID ranges from 1 to 5 percent in published reports . In a systematic literature review, it has been reported a total of 81 ‘treatable inborn errors of metabolism’ presenting with intellectual disability as a major feature, including disorders of amino acids, cholesterol and bile acid, creatine, fatty aldehydes; glucose homeostasis and transport; hyperhomocysteinemia; lysosomes, metals, mitochondria, neurotransmission; organic acids, peroxisomes, pyrimidines, urea cycle, and vitamins/co-factors .
Global metabolomics is based on non-biased quantitative analysis of metabolites in biological samples obtained from healthy (control) and diseased individuals with the aim to identify difference in the endogenous metabolites . Untargeted metabolomics approach aims at measuring simultaneously as many metabolites as possible in a biological sample providing long range of compounds to identify potential biomarkers. Global metabolite profile of urine samples captures the global changes and overall physiological status in biochemical networks and pathways that can be a promising means to identify biomarkers of diseases. Biomarker metabolites can be therapeutic targets . Urine provides a pattern of polar metabolites excreted from the body due to catabolic processes. It is a useful medium for disease diagnosis since it poses various advantages that include non-invasive sample collection, ease of sample repetition and not volume-limited. Urine analysis has easier sample preparation due to lower sample complexity because of low protein and peptide levels. Being a waste product, urine reflects metabolic disregulation and provides insights to changes in response to disease processes .
UPLC-MS is an emerging high throughput powerful tool in the field of metabolomics of biological fluids. It uses smaller particles, speed and peak capacity that results in increase in the resolution, sensitivity and speed of analysis of hundreds of metabolites in a single run . There are no reports for a valid methodology for the detection of urinary markers from ID children for the detection of inborn errors of metabolism that may help in the treatment of the associated metabolic disorders [12-25].
Objectives of the Study
The aim of the present work was to develop an untargeted UPLC-MS based metabolomics approach with multivariate analysis, to screen and identify urine metabolic changes in intellectually disabled children. The focus of the study was on the global metabolite profiling method optimization and validation to identify relevant and putative biomarkers.
Materials and Methods
Chemicals and reagents
HPLC grade Acetonitrile and Formic acid were obtained from Sigma-Aldrich Co., St. Louis, MO, USA. Water was produced by a TKA Smart2Pure Ultra-pure water system (TKA, Germany). All other chemicals used were of HPLC grade.
Subjects and consent
The details of the study were explained to the parents or guardians and school representatives of the participating children, and written informed consent was obtained. Patient samples were collected from Kamayani School for Mentally Challenged, Pune, Maharashtra. Ten participants with ID (n=10; male: 5, female: 5) and control subjects (n=10, male: 5, female: 5) were recruited in the study. Inclusion criterion for the patients was age (9-13 years) with IQ score below 70 and deficit in adaptive functioning that define them as ID. Clinical data was obtained from all the probands including patient’s name, age, gender, IQ score, epilepsy and any other known neuropsychiatric disorders. Under the guidance of a clinician, children without any recognizable syndromes were included in the study as the non-syndromic cohort. Children were not taking any type of medication which can alter the metabolites secreted in the urine. Control subjects included in the study were from a school of the same geographical area not undergoing any special diet or medication. To avoid influence of ageing and gender on metabolic profiles, subjects in the healthy control cohort were matched to corresponding subjects in the ID cohort.
Preparation of urine samples
Random urine samples were collected in sterile urine containers. Sodium azide (0.05% w/v) was added to prevent bacterial contamination. The samples were centrifuged at 10000 rpm for 10 min at 4°C to remove any particulates. The supernatant was transferred to a 2 mL polypropylene tube followed by 1:4 dilution with water and 3 μl of this processed sample was transferred to appropriate LC vials for further analysis.
A 1290 Infinity UHPLC System, 1260 infinity Nano HPLC with Chipcube, 6550 iFunnel Q-TOF (Agilent technologies, USA) was used. Details of the settings for optimized instrument operation and parameters of the protocol are given in Table 1.
|LC Column||Agilent C18 100/150 mm × 2.1 mm 1.7 µm|
|Ionisation||Positive ion Electrospray ionisation (ESI)|
|Injection volume||3 µl|
|Flow rate||0.300 mL/min|
|A: 0.1% formic acid in water|
|B: 90% acetonitrile, 10% water and 0.1% formic acid.|
|LC Gradient program:|
|Time (min)||A (%)||B (%)|
|Sheath gas flow||11 L/min|
|Gas flow rate||13 L/min|
|Nebulizer pressure||35 psi|
|Capillary voltage||3500 V|
|Nozzle voltage||1000 V|
Table 1: UPLC-MS conditions for global urine metabolite profiling.
Data processing and analysis
Data was collected using Agilent Mass Hunter Workstation Data Acquisition software and processed by Agilent MassHunter Qualitative Analysis software (Agilent Technologies, CA, USA). All the raw data .D files were converted to compound exchange format file (.CEF) and were imported to the Mass Profiler Professional (MPP) software (Agilent Technologies, CA, USA) for analysis. Data mining was done using the Molecular Feature Extractor (MFE) algorithm in the MassHunter workstation software. Experimental grouping was done by segregation of patients into two groups according to the parameter healthy (control) versus patients (diseased) respectively. The first filter (abundance filtering) was set at minimum absolute abundance at 5000 counts to reject low-intensity data. All the entities that presented with less than this abundance were considered as noise. The second filter of frequency selected entities that present in at least 50% of all samples. Principal component analysis (PCA) was the algorithm used to detect major trends in the data and a sample quality control check by examining the values of the entities. Un-paired t-test with Benjamini-Hochberg multiple testing correction was used for statistical analysis to filter the entities based on the significant differences in the abundance of compounds between the two groups. Potential metabolite markers were extracted using a statistically significant threshold of fold change values larger than 2.0 and p-values less than 0.05. METLIN Personal Metabolite Database was used for the identification of endogenous and exogenous metabolites. The structure and functional information was then obtained by searching freely accessible database of HMDB (The Human Metabolomic Database), KEGG (Kyoto Encyclopaedia of Genes and Genomics) and HMP (Human Microbiome Project) database.
Twenty subjects, ten patients and ten controls successfully completed the study. Multiple classes of metabolites were successfully detected and identified including peptides, lipids and small molecules. To investigate differences in the metabolic expression signals between healthy volunteers and patients, PCA was first conducted on the datasets under positive ESI ion mode. Score plot obtained from the PCA was used for the unsupervised pattern analysis of all the urine samples (Fig. 1). In the score plot clustering was not clear and PCA did not show any apparent separation between the patients and healthy controls. However, metabolic profiles of some ID group patients significantly changed indicating that there was significant biochemical perturbation. Potential metabolite markers were extracted using a statistically significant threshold of fold values larger than 2.0 and p-values less than 0.05 (unpaired t-test) constructed from the PCA.
Figure 1: 3D PCA score plot of urinary metabolite profile segregating healthy and ID cohort in a population.
Metabolic analysis revealed a total number of 101 metabolites that were differently expressed between the healthy controls and ID patients. Further MPP analysis revealed that among the identified metabolites, eleven metabolites were significantly different in their expression levels. Summary of the metabolites and their regulation is shown in Table 2. UPLC-MS platform could provide the compound name, accurate mass, retention time, CAS number, annotations and regulation information on the identification of these potential biomarkers.
|Sr. no.||Compound||Regulation||Annotations||Mass||Retention time|
|1.||1-Methyl-5-imidazoleacetic acid||Up regulation||C6 H8 N2 O2, CAS ID=4200-48-0, KEGG ID=, METLIN ID=3776||140.058||3.97887|
|2.||6-Hydroxydopamine||Up regulation||C8 H11 N O3, CAS ID=1199-18-4, KEGG ID=, HMP ID=HMDB01537, METLIN ID=6307||169.074||5.24107|
|3.||Dopamine||Up regulation||C8 H11 N O2, CAS ID=51-61-6, KEGG ID=C03758, HMP ID=HMDB00073, METLIN ID=64||153.078||8.08946|
|4.||Erythrono-1,4-lactone||Up regulation||C4 H6 O4, CAS ID=17675-99-9, KEGG ID=, HMP ID=HMDB00349, METLIN ID=5338||118.027||5.53193|
|5.||Glutarylglycine||Up regulation||C7 H11 N O5, CAS ID=17686-38-3, KEGG ID=, HMP ID=HMDB00590, METLIN ID=5569||189.064||5.09047|
|6.||Malonylcarnitine||Up regulation||C10 H17 N O6, CAS ID=853728-01-5, KEGG ID=, HMP ID=HMDB02095||247.106||4.7218|
|7.||O-Acetylserine||Up regulation||C13 H21 N2 O7 P S, CAS ID=5147-00-2, KEGG ID=, HMP ID=HMDB03011, METLIN ID=6809||380.081||5.11285|
|8.||Orinapterin||Up regulation||C9 H11 N5 O3, CAS ID=13039-82-2, KEGG ID=, HMP ID=HMDB00817, METLIN ID=5781||237.087||5.89467|
|9.||Phosphocreatine||Up regulation||C4 H10 N3 O5 P, CAS ID=67-07-2, KEGG ID=, METLIN ID=326||211.036||4.84671|
|10.||Suberic acid||Up regulation||C8 H14 O4, CAS ID=505-48-6, KEGG ID=C08278, HMP ID=HMDB00893, METLIN ID=4243||174.089||9.69879|
|11.||Succinylacetone||Up regulation||C7 H10 O4, CAS ID=51568-18-4, KEGG ID=, HMP ID=HMDB00635, METLIN ID=5608||158.058||3.00343|
Table 2: Metabolites that were differentially expressed in the healthy and patient cohort.
Among these eleven differentially expressed metabolites, three of them are reported earlier to be associated with inborn errors of metabolism along with intellectual disability disorders. The list of these metabolites along with their functions is given in Table 3.
|Sr. no.||Compound name||Description||Reference|
|1.||Dopamine||Aromatic L-amino acid decarboxylase (AADC) deficiency: rare inborn error of neurotransmitter
biosynthesis associated with hyperdopaminuria characterized by global developmental delay.
|, , |
|2.||Glutarylglycine||Glutaric acidemia Type 1: autosomal recessive inborn error of lysine, hydroxylysine, and
tryptophan metabolism. It is reported with urinary elevated levels of glutarylglycine and
delayed treatment leading to mental retardation.
|, , |
|3.||Suberic acid||Medium-chain acyl-CoA dehydrogenase deficiency (MCADD): autosomal recessive hereditary
metabolic disorder of mitochondrial fatty acid ß-oxidation classified as a treatable disorder with
major preventable outcome of intellectual disability.
Table 3: Metabolites reported to be elevated in the urine associated with different inborn errors of metabolism along with intellectual disability.
Eleven metabolites were found to be up regulated in the ID patients. These compounds are identified in normal human urine samples. Five of these are not associated with any specific disease. 1-Methyl-5-imidazoleacetic acid is a known metabolite of Histamine. Erythrono-1,4-lactone has been identified as a lactone of tetronic acid in the urine from normal adults and neonates. O-Acetylserine is an acylated amino acid derivative that arises from either microbial metabolism in the gut or through consumption of foods containing O-Acetylserine. Orinapterin is a threo diastereomer of biopterin found in human urine. 6-Hydroxydopamine is a naturally occurring amine in human urine.
Phosphocreatine is a phosphorylated creatine molecule that serves as a rapidly mobilizable reserve of high-energy phosphates in skeletal muscle and the brain. It is reported with Eosinophilic esophagitis when elevated in the urine. Succinylacetone, a tyrosine metabolite is a specific marker for Tyrosinemia type I which is an inherited metabolism disorder. However its primary effects are liver and kidney dysfunction and is not associated with intellectual disability disorders. Malonylcarnitine is a metabolite that is found to be accumulated in the blood in malonyl-CoA decarboxylase (EC 184.108.40.206) deficiency (OMIM 248360) which typically appears with developmental delay. It is been reported in the human urine, however the effect of its elevated levels are not reported (HMDB). Total three compounds namely, dopamine, glutarylglycine and suberic acid are already reported to be linked to developmental delay.
Dopamine is a member of the catecholamine family in the brain, and is a precursor to epinephrine and norepinephrine. Dopamine is synthesized in the body first by hydration of the amino acid tyrosine DOPA by tyrosine hydroxyalse followed by its decarboxylation by aromatic-L-amino-acid decarboxylase. (PubChem CID: 681) In Aromatic L-amino acid decarboxylase (AADC) deficiency (OMIM 608643), in spite of deficiency of dopamine the patients are found with increased levels of dopamine in their urine and characterised by mental retardation. The reason behind this is explained by Wassenberg et al.  being the combination of residual renal AADC-activity and pathologic increase of L-dopa substrate availability in AADC-deficient patients. Coexistence of cognitive deficits and neuropathology indicates that defective neurotransmission in the central nervous system may lead to intellectual disability disorders .
Glutarylglycine is an acyl glycine (PubChem CID: 23592950). Acyl glycines are normal intermediates of amino acid and fatty acid metabolism. However, in elevated concentrations they are biochemical markers in several inborn errors of metabolism. Glutarylglycine is involved in lysine metabolism (HMDB). Glutaric acidemia type 1 (OMIM 231670) is an inherited disorder in which body is unable to break down the amino acids lysine, hydroxylysine and tryptophan caused by deficiency of mitochondrial glutaryl-CoA dehydrogenase. Excessive levels of their intermediate breakdown products (Glutaric acid, hydroxyglutaric acid, glutaconic acid and glutarylglycine) accumulate and cause damage to the brain, particularly basal ganglia causing irreversible neurological damage. These intermediates are found elevated in the urine presenting as potential biomarkers for the identification of the condition. Delayed treatment worsens the condition of the patient resulting in significant mental retardation.
Suberic acid, also octanedioic acid, is a dicarboxylic acid (PubChem CID: 10457). It is a metabolic breakdown product derived from oleic acid. Suberic acid is detected in the urine of patients with fatty acid mitochondrial disorders . Substantial excretion of suberic acid has been reported in the urinary analysis of patients with medium-chain acyl-CoA dehydrogenase deficiency . Medium-chain Acyl-CoA dehydrogenase (EC 220.127.116.11) is one of the enzymes involved in mitochondrial fatty acid oxidation, which fuels hepatic ketogenesis. Deficiency of the enzyme causes incomplete beta-oxidation resulting in increased levels of suberic acid in the urine. Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCADD; OMIM 607008) is the most common inherited disorder of mitochondrial fatty acid b-oxidation in humans. Various developmental disabilities are found associated with MCADD including intellectual disability, cerebral palsy and autism spectrum disorders.
Literature suggests variable diagnostic yield of metabolic testing ranging from 0.8 to 13 percent. However, inborn errors of metabolism represent largest group of genetic defects associated with ID amenable to causal therapy . Without early detection, at least 50 percent of the children will experience metabolic crisis and up to 10 percent of the survivors will develop a serious developmental disability. There are reports for method validation for metabolic profiling analysis of urine samples using UPLC–TOFMS [21-25]. Although there are no reports of global urine metabolite profiling using UPLCMS technique to identify inborn errors of metabolism associated with intellectual disability.
Our findings indicate that urinary metabolites may allow the segregation of ID patients from normal individuals and may reflect the underlying biology of ID, which is still largely unknown. Further validation of the methodology and parameters on a larger population may provide novel instincts into the etiology of ID and help in the identification of urinary metabolites as biomarkers by a non-invasive technique.
The study was financially supported by University Grants Commission-University with Potential for Excellence [UGC-UPE 262 (B) (2)] grant. We thank the Kamayani School for Mentally Challenged, Pune, Maharashtra who provided and cared for study patients. We acknowledge SAIF (Sophisticated Analytical Instrumentation Facility), IIT Bombay for the UPLC-MS run and MPP data analysis.
- Sun H, Zhang A, Yan G, et al. Metabolic analysis of key regulatory metabolites in hepatitis C virus-infected tree shrews. Mol Cell Proteomics. 2013; 3:710-9.
- Worley B, Powers R. Multivariate. Analysis in Metabolomics. Curr Metabolomics. 2013; 1:92-107
- Salvador-Carull L, Reed GM, Vaez-Azizi LM, et al. Intellectual developmental disorders: Towards a new name, definition and framework for ?mental retardation/intellectual disability? in ICD-11. World Psychiatry. 2011; 10: 175-80.
- Kaufman L, Ayub M, Vincent JB. The genetic basis of non-syndromic intellectual disability: A review. J Neurodev Disord. 2010; 2:182-209.
- Sempere A, Arias A, Farré G, et al. Study of inborn errors of metabolism in urine from patients with unexplained mental retardation. J Inherit Metab Dis. 2010; 33:1-7.
- García-Cazorla A, Wolf NI, Serrano M, et al. Mental retardation and inborn errors of metabolism. J Inherit Metab Dis. 2009; 32:597-608.
- Van Karnebeek CD, Stockler S. Treatable inborn errors of metabolism causing intellectual disability: A systematic literature review. Mol Genet Metab. 2012; 105:368-81.
- Waybright TJ, Van QN, Muschik GM, et al. LC-MS in Metabonomics: Optimization of experimental conditions for the analysis of metabolites in human urine. Journal of Liquid Chromatography & Related Technologies. 2006; 29:2475-97.
- Zhang A, Sun H, Han Y, et al. Exploratory urinary metabolic biomarkers and pathways using UPLC-Q-TOF-HDMS coupled with pattern recognition approach. Analyst. 2012; 137:4200?8.
- Nunes DPMJ, Menezes HC, De LCZ. Sampling and analysis of metabolomes in biological fluids. Analyst. 2014; 139(15):3683-94.
- Chaoyang M, Liming H, Guanjun T, et al. An UPLC-MS-based metabolomics investigation on the anti-fatigue effect of salidroside in mice. Journal of Pharmaceutical and Biomedical Analysis. 2015; 105:840-90.
- Wassenberg T, Monnens LAH, Geurtz PBH, et al. The paradox of hyperdopaminuria in aromatic L-amino acid deficiency explained. JIMD Rep. 2011; 4:39-45.
- Bhowmik AD, Chaudhury S, Dutta S, et al. Role of functional dopaminergic gene polymorphisms in the etiology of idiopathic intellectual disability. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35:1714-22.
- La Marca GC, Rizzo C. Analysis of organic acids and acylglycines for the diagnosis of related inborn errors of metabolism by GC- and HPLC-MS. Methods Mol Biol. 2011; 708:73-98.
- Viau K, Ernst SL, Vanzo RJ, et al. Glutaric acidemia Type 1: Outcomes before and after expanded newborn screening. Mol Genet Metab. 2012; 106:430-438.
- Sherman EA, Strauss KA, Tortorelli S, et al. Genetic mapping of glutaric aciduria, type 3, to chromosome 7 and identification of mutations in C7orf10. Am J Hum Genet. 2008; 83:604-9
- Yang L, Yin H, Yang R, et al. Diagnosis, treatment and outcome of glutaric aciduria type I in Zhejiang Province, China. Med Sci Monit. 2011; 17(7):55-59.
- Hagena T, Korsonb MS, Sakamoto M, et al. A GC/MS/MS screening method for multiple organic acidemias from urine specimens. Clinica Chimica Acta. 1999; 283:77?88.
- Woo HI, Park HD, Lee Y, et al. Clinical, biochemical and genetic analyses in two Korean patients with medium-chain acyl-CoA dehydrogenase deficiency. Korean J Lab Med. 2011; 31:54-60.
- Van KCD, Stockler-Ipsiroglu S. Early identification of treatable inborn errors of metabolism in children with intellectual disability: The Treatable Intellectual Disability Endeavor protocol in British Columbia. Paediatr Child Health. 2014; 19(9):469-71.
- Guy PA, Tavazzi I, Bruce SJ, et al. Journal of Chromatography B. 2008; 871: 253-260.
- Wassenberg T, Willemsen MAAP, Geurtz PBH, et al. Urinary dopamine in aromatic L-amino acid decarboxylase deficiency: The unsolved paradox. Mol Genet Metab. 2010; 101:349-56.
- Ito S, Nakayama T, Ide S, et al. Aromatic L-amino acid decarboxylase deficiency associated with epilepsy mimicking non-epileptic involuntary movements. Dev Med Child Neurol. 2008; 50:876-78.
- Hedlund GL, Longo N, Pasquali M. Glutaric Acidemia Type 1. Am J Med Genet C Semin Med Genet. 2006; 142C(2):86-94.
- Grosse SD, Khoury MJ, Greene CL, et al. The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: An update. Genet Med. 2006; 8(4):205-12.